Catlog No. | Cell Name | Growth Property | Morphology | Species | Disease | Organ/Type | Subtype | Cell Origin | Origininal Cat# | Growth Medium |
NGTCBBLA001 | 1A6 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | PTA-556 | RPMI1640 + 10% FBS | |
NGTCBBLA002 | 5637 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | HTB-9 | RPMI1640 + 10% FBS | |
NGTCBBLA003 | 647V | Adherent | Epithelial | Human | Bladder Cancer | Bladder | DSMZ | ACC 414 | 85% Dulbecco's MEM + 15% FBS + 2 mM L-glutamine | |
NGTCBBLA004 | 97-7 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | COSMIC | N/A | Ham F12 Nutrient mixture + 1% FBS+ 1% Insulin-Transferrin-Selenium + 1% NEAA +1% L Glutamine + 1ng/ml Hydrocortisone | |
NGTCBBLA005 | BFTC-905 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | DSMZ | ACC 361 | 80-90% Dulbecco's MEM + 10-20% h.i. FBS | |
NGTCBBLA006 | HT-1197 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | CRL-1473 | MEM + 10% FBS | |
NGTCBBLA007 | HT-1376 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | CRL-1472 | MEM + 10% FBS + 1% NEAA | |
NGTCBBLA008 | HT1080 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | Fibrosarcoma | ECACC | 85111505 | MEM + 10% FBS + 1% NEAA |
NGTCBBLA009 | J82 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | HTB-1 | MEM + 10% FBS + 1% NEAA + 1% Sodium Pyruvate | |
NGTCBBLA010 | KU-19-19 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | DSMZ | ACC 395 | RPMI1640 + 10% FBS | |
NGTCBBLA011 | MGHU3 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | N/A | N/A | aMEME + 10% FBS | |
NGTCBBLA012 | RT112/84 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ECACC | 85061106 | MEM + 10% FBS + 1% NEAA | |
NGTCBBLA013 | RT4 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | HTB-2 | McCoy's 5a + 10% FBS | |
NGTCBBLA014 | SCaBER | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | HTB-3 | MEM + 10% FBS + 1% NEAA | |
NGTCBBLA015 | SW1710 | Adherent | Fibroblast | Human | Bladder Cancer | Bladder | N/A | N/A | RPMI1640 + 10% FBS | |
NGTCBBLA016 | SW780 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | CRL-2169 | L15 + 10% FBS | |
NGTCBBLA017 | T24 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | HTB-4 | RPMI1640 + 10% FBS | |
NGTCBBLA018 | TCC-SUP | Adherent | Epithelial | Human | Bladder Cancer | Bladder | DSMZ | ACC 377 | MEM + 10% FBS + 1% NEAA | |
NGTCBBLA019 | UM-UC-3 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | ATCC | CRL-1749 | MEM + 10% FBS + 1% NEAA + 1% Soudium Pyruvate | |
NGTCBBLA020 | VM-CUB-1 | Adherent | Epithelial | Human | Bladder Cancer | Bladder | DSMZ | ACC 400 | DMEM + 10% FBS | |
NGTCBBON001 | MG-63 | Adherent | Fibroblast | Human | Bone Osteosarcoma | Bladder | ATCC | CRL-1427 | MEM + 10% FBS | |
NGTCBBRA001 | T98-G | Adherent | Fibroblast | Human | Brain Tumor | Brain | Glioblastoma multiforme | ATCC | CRL-1690 | MEM + 10% FBS |
NGTCBBRA002 | U-87 MG | Adherent | Epithelial | Human | Brain Tumor | Brain | Glioblastoma; astrocytoma | ATCC | HTB-14 | MEM + 10% FBS |
NGTCBBRE001 | 4T1 | Adherent | Epithelial | Mouse | Breast Cancer | Mammary gland | ATCC | CRL-2539 | RPMI1640 + 10% FBS | |
NGTCBBRE002 | BT-20 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | ATCC | HTB-19 | DMEM + 10% FBS + 10 ug/ml Insulin | |
NGTCBBRE003 | BT-474 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | HTB-20 | ATCC Hybri-Care Medium + 1.5 g/L Sodium Bicarbonate + 10% FBS |
NGTCBBRE004 | BT-483 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | HTB-121 | DMEM + 20% FBS + 10 ug/ml bovine insulin |
NGTCBBRE005 | BT-549 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | HTB-122 | DMEM + 0.23 IU/ml insulin + 10% FBS |
NGTCBBRE006 | CAL-120 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | DSMZ | ACC 459 | RPMI1640 + 10% FBS | |
NGTCBBRE007 | CAL-51 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | DSMZ | ACC 302 | DMEM + 20% FBS |
NGTCBBRE008 | CAMA-1 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | ATCC | HTB-21 | MEM + 10% FBS |
NGTCBBRE009 | EFM-192A | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | DSMZ | ACC 258 | 80% RPMI 1640 + 20% h.i. FBS + 2 mM L-glutamine | |
NGTCBBRE010 | HCC1143 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-2321 | RPMI1640 + 10% FBS |
NGTCBBRE011 | HCC1187 | Mixed suspension and adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-2322 | RPMI1640 + 10% FBS |
NGTCBBRE012 | HCC1395 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-2324 | RPMI1640 + 10% FBS |
NGTCBBRE013 | HCC1419 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-2326 | RPMI1640 + 10% FBS |
NGTCBBRE014 | HCC1569 | Mixed suspension and adherent | Epithelial | Human | Breast Cancer | Mammary gland | Metaplastic carcinoma | ATCC | CRL-2330 | RPMI1640 + 10% FBS |
NGTCBBRE015 | HCC1806 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Squamous cell carcinoma | ATCC | CRL-2335 | RPMI1640 + 10% FBS |
NGTCBBRE016 | HCC1937 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-2336 | RPMI1640 + 10% FBS |
NGTCBBRE017 | HCC1954 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-2338 | RPMI1640 + 10% FBS |
NGTCBBRE018 | HCC70 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-2315 | RPMI1640 + 10% FBS |
NGTCBBRE019 | Hs 578T | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | ATCC | HTB-126 | DMEM + 10% FBS +10 ug/ml insulin |
NGTCBBRE020 | JIMT-1 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | DSMZ | ACC 589 | DMEM + 10% FBS |
NGTCBBRE021 | KPL-4 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | N/A | N/A | RPMI 1640 + 10% FBS | |
NGTCBBRE022 | MCF 10A | Adherent | Epithelial | Human | Fibrocystic disease | Mammary gland | ATCC | CRL-10317 | MEBM kit +100 ng/ml cholera toxin | |
NGTCBBRE023 | MCF-7/mdr+ | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | N/A | N/A | DMEM + 10% FBS |
NGTCBBRE024 | MCF7 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | ATCC | HTB-22 | DMEM + 10% FBS |
NGTCBBRE025 | MDA-MB-134VI | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | HTB-23 | ATCC-formulated Leibovitz's L-15 Medium + 20% FBS |
NGTCBBRE026 | MDA-MB-157 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Medulallary carcinoma | ATCC | HTB-24 | L15 + 10% FBS |
NGTCBBRE027 | MDA-MB-175 VII | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | HTB-25 | L15 + 20% FBS |
NGTCBBRE028 | MDA-MB-231 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | ATCC | HTB-26 | L15 + 10% FBS |
NGTCBBRE029 | MDA-MB-361 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | ATCC | HTB-27 | L15 + 10% FBS |
NGTCBBRE030 | MDA-MB-415 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | ATCC | HTB-128 | L-15 + 10 ug/ml insulin + 10 ug/ml glutathione + 15% FBS |
NGTCBBRE031 | MDA-MB-436 | Adherent | Pleomorphic with multinucleated component cells | Human | Breast Cancer | Mammary gland | Adenocarcinoma | ATCC | HTB-130 | L-15 + 10 ug/ml insulin+16 ug/ml glutathione+10% FBS |
NGTCBBRE032 | MDA-MB-453 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Metastatic carcinoma | ATCC | HTB-131 | L-15 + 10% FBS |
NGTCBBRE033 | MDA-MB-468 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | ATCC | HTB-132 | DMEM + 10% FBS |
NGTCBBRE034 | SK-BR-3 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Adenocarcinoma | ATCC | HTB-30 | McCoy's 5a + 10% FBS |
NGTCBBRE035 | SUM52PE | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | HAMS F12 + 5% FCS + 5 ug/ml Insulin + 1 ug/ml Hydrocortisone | |||
NGTCBBRE036 | T-47D | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | HTB-133 | DMEM +10% FBS |
NGTCBBRE037 | UACC812 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-1897 | L-15 + 20 ng/ml human EGF + 20% FBS |
NGTCBBRE038 | UACC893 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | ATCC | CRL-1902 | L15 + 10% FBS | |
NGTCBBRE039 | ZR-75-1 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-1500 | RPMI1640 + 10% FBS + 10ug/ml insuline |
NGTCBBRE040 | ZR-75-30 | Adherent | Epithelial | Human | Breast Cancer | Mammary gland | Ductal Carcinoma | ATCC | CRL-1504 | RPMI1640 + 10% FBS |
NGTCBCER001 | Hela | Adherent | Epithelial | Human | Cervical Carcinoma | Cervix | RPMI1640 + 10% FBS | |||
NGTCBCER002 | ME 180 | Adherent | Epithelial | Human | Cervical Carcinoma | Cervix | RPMI1640 + 10% FBS | |||
NGTCBCOL001 | BE | Adherent | Epithelial | Human | Colorectal Cancer | Colon | DMEM + 10% FBS | |||
NGTCBCOL002 | C-75 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | IMDM + 10% FBS (Incubate at 10% CO2) | |||
NGTCBCOL003 | C-99 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | IMDM + 10% FBS (Incubate at 10% CO2) | |||
NGTCBCOL004 | CC-20 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | DMEM + 10% FBS (Incubate at 10% CO2) | |||
NGTCBCOL005 | CCK-81 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma | JCRB | JCRB0208 | DMEM + 10% FBS (Incubate at 10% CO2) |
NGTCBCOL006 | COLO 205 | Mixed suspension and adherent | Epithelial | Human | Colorectal Cancer | Colon | Dukes/ type D | ATCC | CCL-222 | DMEM + 10% FBS |
NGTCBCOL007 | COLO 320DM | Mixed suspension and adherent | Epithelial | Human | Colorectal Cancer | Colon | Dukes/ type C | ATCC | CCL-220 | RPMI1640 + 10% FBS |
NGTCBCOL008 | CaCO2 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Grade II | ECACC | 86010202 | DMEM + 10% FBS |
NGTCBCOL009 | HCA-7 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Dukes/ type B | ECACC | 6061902 | DMEM + 10% FBS (Incubate at 10% CO2) |
NGTCBCOL010 | HCT 116 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | ATCC | CCL-247 | McCoy's 5a +10% FBS | |
NGTCBCOL011 | HCT-15 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes' type C | ATCC | CCL-225 | RPMI1640 + 10% FBS |
NGTCBCOL012 | HCT-8 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Ileocecal colorectal adenocarcinoma | ATCC | CCL-244 | RPMI1640 + 10% FBS |
NGTCBCOL013 | HRA-19 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | IMDM + 10% FBS (Incubate at 10% CO2) | |||
NGTCBCOL014 | HT29 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma | ATCC | HTB-38 | RPMI1640 + 10% FBS |
NGTCBCOL015 | LOVO | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes type C, grade IV | ATCC | CCL-229 | DMEM + 10% FBS |
NGTCBCOL016 | LS 180 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes type B | ATCC | CL-187 | MEM + 10% FBS |
NGTCBCOL017 | LS1034 | Adherent | Epithelial | Human | Colorectal Cancer | Cecum | Dukes type C | ATCC | CRL-2158 | RPMI1640 + 10% FBS |
NGTCBCOL018 | LS174T | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes' type B | ATCC | CL-188 | RPMI1640 + 10% FBS |
NGTCBCOL019 | RKO | Adherent | Epithelial | Human | Colorectal Cancer | Colon | ATCC | CRL-2577 | MEM + 10% FBS | |
NGTCBCOL020 | SK-CO-1 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma | ATCC | HTB-39 | MEM + 10% FBS |
NGTCBCOL021 | SL4 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | RPMI1640 + 10% FBS | |||
NGTCBCOL022 | SNU-1040 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | RPMI1640 + 300 mg/L L-glutamine + 25 mM HEPES + 25 mM NaHCO3 +10% hiFBS | |||
NGTCBCOL023 | SNU-407 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | RPMI1640 + 300 mg/L L-glutamine + 25 mM HEPES + 25 mM NaHCO3 +10% hiFBS | |||
NGTCBCOL024 | SW1417 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes type C, grade III | ATCC | CCL-238 | L-15 + 10% FBS |
NGTCBCOL025 | SW403 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes type C, grade III | ATCC | CCL-230 | L-15 + 10% FBS |
NGTCBCOL026 | SW48 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes type C, grade IV | ATCC | CCL-231 | L-15 + 10% FBS |
NGTCBCOL027 | SW480 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes' type B | ATCC | CCL-228 | L-15 + 10% FBS |
NGTCBCOL028 | SW620 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes' type C | ATCC | CCL-227 | L-15 + 10% FBS |
NGTCBCOL029 | SW948 | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma, Dukes type C, grade III | ATCC | CCL-237 | L-15 + 10% FBS |
NGTCBCOL030 | WIDR | Adherent | Epithelial | Human | Colorectal Cancer | Colon | Adenocarcinoma | ATCC | CCL-218 | MEM + 10% FBS |
NGTCBEND001 | AN3CA | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | ATCC | HTB-111 | MEM + 10% FBS |
NGTCBEND002 | EFE-184 | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | DSMZ | ACC 230 | RPMI1640:MEM (1:1) + 20% FBS + 10 ug/ml insulin |
NGTCBEND003 | EN | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | RPMI1640 + 10% FBS | ||
NGTCBEND004 | HEC-1-A | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | ATCC | HTB-112 | McCoy's 5a +10% FBS |
NGTCBEND005 | HEC-1-B | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | ATCC | HTB-113 | MEM + 10% FBS |
NGTCBEND006 | KLE | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | RPMI1640 + 10% FBS | ||
NGTCBEND007 | MFE-280 | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | ECACC | 98050131 | 40% RPMI1640 + 40% MEM + 20% FBS + 1x insulin-transferrin-sodium selenite |
NGTCBEND008 | MFE-296 | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | ECACC | 98031101 | MEM + 10% FBS |
NGTCBEND009 | RL95-2 | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | MEM + 10% FBS | ||
NGTCBEND010 | SK-UT-1 | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterus | Mesodermal tumor (mixed), Grade III | ATCC | HTB-114 | MEM + 10% FBS |
NGTCBEND011 | SK-UT-1B | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Mesodermal tumor (mixed), Grade III | ATCC | HTB-115 | MEM + 10% FBS |
NGTCBEND012 | SNG-M | Adherent | Epithelial | Human | Endometrial Carcinoma | Uterine endometrium | Adenocarcinoma | JCRB | IF050313 | F12 + 10% FBS |
NGTCBESO001 | Bic-1 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO002 | Colo-680N | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | DSMZ | ACC 182 | RPMI1640 + 10% FBS |
NGTCBESO003 | EC9706 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO004 | ECa 109 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO005 | KYSE140 | Adherent | Fibroblast | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | DSMZ | ACC 348 | RPMI1640 + 10% FBS |
NGTCBESO006 | KYSE180 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | JCRB | JCRB1093 | RPMI1640 + 10% FBS |
NGTCBESO007 | KYSE30 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | ECACC | 94072011 | RPMI1640 + 10% FBS |
NGTCBESO008 | KYSE450 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | DSMZ | ACC 387 | RPMI1640 + 10% FBS |
NGTCBESO009 | KYSE510 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | DSMZ | ACC 374 | RPMI1640 + 10% FBS |
NGTCBESO010 | KYSE70 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | ECACC | 94072012 | RPMI1640 + 10% FBS |
NGTCBESO011 | OACP4C | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO012 | SKGT4 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO013 | Seg1 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO014 | T.T | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | JCRB | JCRB0262 | DMEM/F12 (1:1) + 10% FBS |
NGTCBESO015 | T.Tn | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | JCRB | JCRB0261 | DMEM/F12 (1:1) + 10% FBS |
NGTCBESO016 | TE-15 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | RCB | RCB1951 | RPMI1640 + 10% FBS |
NGTCBESO017 | TE-4 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | Squamous cell carcinoma | RCB | RCB2097 | RPMI1640 + 10% FBS |
NGTCBESO018 | TE10 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO019 | TE12 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO020 | TE3 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO021 | TE7 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBESO022 | Yes2 | Adherent | Epithelial | Human | Esophageal Cancer | Esophagus | RPMI1640 + 10% FBS | |||
NGTCBGAS001 | 23132/87 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | DSMZ | ACC 201 | RPMI1640 + 10% FBS |
NGTCBGAS002 | AGS | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | ATCC | CRL-1739 | RPMI1640 + 10% FBS |
NGTCBGAS003 | AZ-521 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB0061 | RPMI1640 + 10% FBS | |
NGTCBGAS004 | BGC-823 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | RPMI1640 + 10% FBS | |||
NGTCBGAS005 | FU97 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | JCRB | JCRB1074 | RPMI1640 + 10% FBS |
NGTCBGAS006 | GTL16 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | RPMI1640 + 10% FBS | |||
NGTCBGAS007 | HGC27 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | ECACC | 94042256 | RPMI1640 + 10% FBS | |
NGTCBGAS008 | HS746T | Adherent | Epithelial | Human | Gastric Cancer | Stomach | ATCC | HTB-135 | DMEM + 10% FBS + 1% NEAA + 1% Sodium Pyruvate | |
NGTCBGAS009 | IM95 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB1075.0 | DMEM + 10% FBS + 10 ug/ml insulin | |
NGTCBGAS010 | KATO III | Mixed suspension and adherent | Epithelial | Human | Gastric Cancer | Stomach | ATCC | HTB-103 | RPMI1640 + 10% FBS | |
NGTCBGAS011 | KE-39 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | RCB | RCB1434 | RPMI1640 + 10% FBS | |
NGTCBGAS012 | MGC803 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | RPMI1640 + 10% FBS | |||
NGTCBGAS013 | MKN1 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB0252 | RPMI1640 + 10% FBS | |
NGTCBGAS014 | MKN28 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB0253 | RPMI1640 + 10% FBS | |
NGTCBGAS015 | MKN45 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB0254 | RPMI1640 + 10% FBS | |
NGTCBGAS016 | MKN7 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB1025 | RPMI1640 + 10% FBS | |
NGTCBGAS017 | MKN74 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | JCRB | JCRB0254 | RPMI1640 + 10% FBS |
NGTCBGAS018 | NCI-N87 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | ATCC | CRL-5822 | RPMI1640 + 10% FBS | |
NGTCBGAS019 | NUGC-2 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB0821 | RPMI1640 + 10% FBS | |
NGTCBGAS020 | NUGC-3 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB0822 | RPMI1640 + 10% FBS | |
NGTCBGAS021 | NUGC-4 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB0834 | RPMI1640 + 10% FBS | |
NGTCBGAS022 | OCUM-1 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | JCRB | JCRB0192 | DMEM + 1% Soudium Pyruvate + 10% FBS |
NGTCBGAS023 | OE19 | Adherent | Epithelial | Human | Gastric Cancer | Oesophagus/gastric cardia | ECACC | 96071721 | RPMI1640 + 10% FBS | |
NGTCBGAS024 | OE33 | Adherent | Epithelial | Human | Gastric Cancer | Oesophagus | ECACC | 96070808 | RPMI1640 + 10% FBS | |
NGTCBGAS025 | PAMC82 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | RPMI1640 + 10% FBS | |||
NGTCBGAS026 | PHM82 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | RPMI1640 + 10% FBS | |||
NGTCBGAS027 | SCH | Adherent | Epithelial | Human | Gastric Cancer | Stomach | JCRB | JCRB0251 | RPMI1640 + 10% FBS | |
NGTCBGAS028 | SGC7901 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | RPMI1640 + 10% FBS | ||
NGTCBGAS029 | SNU-1 | Suspension | Epithelial | Human | Gastric Cancer | Stomach | ATCC | CRL-5971 | RPMI1640 + 10% FBS | |
NGTCBGAS030 | SNU-16 | Suspension | Epithelial | Human | Gastric Cancer | Stomach | ATCC | CRL-5974 | RPMI1640 + 10% FBS | |
NGTCBGAS031 | SNU-216 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | KCLB | 216 | RPMI1640 + 10% FBS |
NGTCBGAS032 | SNU-484 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | KCLB | 484 | RPMI1640 + 10% FBS |
NGTCBGAS033 | SNU-5 | Suspension | Epithelial | Human | Gastric Cancer | Stomach | ATCC | CRL-5973 | RPMI1640 + 10% FBS | |
NGTCBGAS034 | SNU-520 | Suspension | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | KCLB | 520 | RPMI1640 + 10% FBS |
NGTCBGAS035 | SNU-601 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | signet ring cell | KCLB | 601 | RPMI1640 + 10% FBS |
NGTCBGAS036 | SNU-620 | Suspension | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | KCLB | 620 | RPMI1640 + 10% FBS |
NGTCBGAS037 | SNU-638 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | KCLB | 638 | RPMI1640 + 10% FBS |
NGTCBGAS038 | SNU-668 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | signet ring cell | KCLB | 668 | RPMI1640 + 10% FBS |
NGTCBGAS039 | SNU-719 | Adherent | Epithelial | Human | Gastric Cancer | Stomach | Adenocarcinoma | KCLB | 719 | RPMI1640 + 10% FBS |
NGTCBHEP001 | BEL7402 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | SIMM | RPMI1640 + 10% FBS | ||
NGTCBHEP002 | BEL7404 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | SIBS | RPMI1640 + 10% FBS | ||
NGTCBHEP003 | BEL7405 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | SIBS | RPMI1640 + 10% FBS | ||
NGTCBHEP004 | H22 | Suspension | Epithelial | Mouse | Hepatocellular Carcinoma | Liver | CCTCC | RPMI1640 + 10% FBS | ||
NGTCBHEP005 | HCCLM3 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | SIBS | RPMI1640 + 10% FBS | ||
NGTCBHEP006 | HCCLM6 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | SIBS | DMEM + 10% FBS | ||
NGTCBHEP007 | HLE | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | JCRB | JCRB0404 | DMEM + 10% FBS | |
NGTCBHEP008 | HLF | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | JCRB | JCRB0405 | DMEM + 5% FBS | |
NGTCBHEP009 | Hep3B | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | ATCC | HB-8064 | MEM + 10% FBS | |
NGTCBHEP010 | HepG2 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | ATCC | HB-8065 | RPMI1640 + 10% FBS | |
NGTCBHEP011 | HuH-1 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | JCRB | JCRB0199 | DMEM + 10% FBS | |
NGTCBHEP012 | HuH-7 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | JCRB | JCRB0403 | DMEM + 10% FBS | |
NGTCBHEP013 | MHCC97 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | DMEM + 10% FBS | |||
NGTCBHEP014 | McA-RH7777 | Adherent | Epithelial | Rat | Hepatocellular Carcinoma | Liver | ATCC | CRL-1601 | DMEM + 10% FBS | |
NGTCBHEP015 | PLC/PRF/5 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | ATCC | CRL-8024 | RPMI1640 + 10% FBS | |
NGTCBHEP016 | QGY7701 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | SIBS | RPMI1640 + 10% FBS | ||
NGTCBHEP017 | QGY7703 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | SIBS | DMEM + 10% FBS | ||
NGTCBHEP018 | SK-HEP-1 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | Adenocarcinoma | ATCC | HTB-52 | RPMI1640 + 10% FBS |
NGTCBHEP019 | SMMC-7721 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | SIMM | RPMI1640 + 10% FBS | ||
NGTCBHEP020 | SNU-182 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | Grade III/IV | ATCC | CRL-2235 | RPMI1640 + 10% FBS |
NGTCBHEP021 | SNU-354 | Adherent | Polygonal | Human | Hepatocellular Carcinoma | Liver | Grade II-III/IV | KCLB | 354 | RPMI1640 + 10% FBS |
NGTCBHEP022 | SNU-368 | Adherent | Polygonal | Human | Hepatocellular Carcinoma | Liver | Grade II-IV/IV | KCLB | 368 | RPMI1640 + 10% FBS |
NGTCBHEP023 | SNU-387 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | Grade IV/V | ATCC | CRL-2237 | RPMI1640 + 10% FBS |
NGTCBHEP024 | SNU-398 | Mixed suspension and adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | ATCC | CRL-2233 | RPMI1640 + 10% FBS | |
NGTCBHEP025 | SNU-423 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | Grade III/IV | ATCC | CRL-2238 | RPMI1640 + 10% FBS |
NGTCBHEP026 | SNU-449 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | Grade II-III/IV | ATCC | CRL-2234 | RPMI1640 + 10% FBS |
NGTCBHEP027 | SNU-475 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | Grade II-IV/IV | ATCC | CRL-2236 | RPMI1640 + 10% FBS |
NGTCBHEP028 | SNU-739 | Adherent | Spindle | Human | Hepatocellular Carcinoma | Liver | KCLB | 739 | RPMI1640 + 10% FBS | |
NGTCBHEP029 | SNU-761 | Adherent | Polygonal | Human | Hepatocellular Carcinoma | Liver | KCLB | 761 | RPMI1640 + 10% FBS | |
NGTCBHEP030 | SNU-878 | Adherent | Epithelial | Human | Hepatocellular Carcinoma | Liver | KCLB | 878 | RPMI1640 + 10% FBS | |
NGTCBHEP031 | SNU-886 | Adherent | Polygonal | Human | Hepatocellular Carcinoma | Liver | KCLB | 886 | RPMI1640 + 10% FBS | |
NGTCBHEP032 | Zip-177 | Adherent | Epithelial | Mouse | Hepatocellular Carcinoma | Liver | SIMM | RPMI1640 + 10% FBS | ||
NGTCBCHO001 | HCCC9810 | Adherent | Epithelial | Human | Intra-Cholangiocarcinoma | Bile duct | SIBS | DMEM + 10% FBS | ||
NGTCBKID001 | 786-O | Adherent | Epithelial | Human | Kidney Cancer | Kidney | Renal cell adenocarcinoma | ATCC | CRL-1932 | RPMI1640 + 10% FBS |
Caki-1 | Adherent | Epithelial | Human | Kidney Cancer | Kidney | Clear cell carcinoma | ATCC | HTB-46 | McCoy's 5a +10% FBS | |
NGTCBLEU001 | AMO-1 | Suspension | Round cell | Human | Leukemia | Blood | Plasmacytoma | DSMZ | ACC 538 | RPMI1640 +20% FBS |
NGTCBLEU002 | ARH-77 | Suspension | Round cell | Human | Leukemia | Blood | Plasma cell leukemia | ATCC | ACRL-1621 | RPMI1640 + 10% FBS |
NGTCBLEU003 | CMK | Suspension | Round cell | Human | Leukemia | Blood | Acute megakaryocytic leukemia | DSMZ | ACC 392 | 80-90% RPMI 1640 + 10-20% FBS |
NGTCBLEU004 | HEL 92.1.7 | Suspension | Round cell | Human | Leukemia | Blood | Erythroleukemia | ATCC | TIB-180 | RPMI1640 + 10% FBS |
NGTCBLEU005 | HL60 | Suspension | Round cell | Human | Leukemia | Blood | Acute promyelocytic leukemia | ATCC | CCL-240 | RPMI1640 + 10% FBS |
NGTCBLEU006 | JURKAT | Suspension | Round cell | Human | Leukemia | Blood | Plasma cell leukemia | DSMZ | ACC 282 | DMEM/IMDM(1:1) + 20% FBS |
NGTCBLEU007 | JVM 3 | Suspension | Round cell | Human | Leukemia | Blood | Chronic B cell leukemia | DSMZ | ACC 18 | RPMI1640 + 10% FBS |
NGTCBLEU008 | K-562 | Suspension | Round cell | Human | Leukemia | Blood | Plasma cell leukemia | DSMZ | ACC 541 | DMEM/IMDM(1:1) + 20% FBS |
NGTCBLEU009 | KG-1 | Suspension | Round cell | Human | Leukemia | Blood | Acute myelogenous leukemia | ATCC | CCL-246 | IMDM + 20% FBS |
NGTCBLEU010 | L-363 | Suspension | Round cell | Human | Leukemia | Blood | Plasma cell leukemia | DSMZ | ACC 49 | 85% RPMI 1640 + 15% FBS |
NGTCBLEU011 | MEC-1 | Suspension | Round cell | Human | Leukemia | Blood | Chronic B cell leukemia | DSMZ | ACC 497 | IMDM + 10% FBS |
NGTCBLEU012 | MOLM-13 | Suspension | Round cell | Human | Leukemia | Blood | Human acute myeloid leukemia | DSMZ | ACC 554 | RPMI1640 + 10% FBS |
NGTCBLEU013 | MOLM-16 | Suspension | Round cell | Human | Leukemia | Blood | Human acute myeloid leukemia | DSMZ | ACC 555 | 60-65% RPMI 1640 + 20% FBS + 15-20% vol conditioned medium of cell line 5637 |
NGTCBLEU014 | MV-4-11 | Suspension | Round cell | Human | Leukemia | Blood | Myelomonocytic | ATCC | CRL-9591 | IMDM + 10% FBS |
NGTCBLEU015 | MonoMac6 | Suspension | Round cell | Human | Leukemia | Blood | Human acute monocytic leukemia | DSMZ | ACC 124 | RPMI 1640 + 10% FBS + NEAA + 1 mM sodium pyruvate + 10 ug¸/ml human insulin |
NGTCBLEU016 | NOMO-1 | Suspension | Round cell | Human | Leukemia | Blood | Human acute myeloid leukemia | DSMZ | ACC 542 | RPMI1640 + 10% FBS |
NGTCBLEU017 | OCI-AML2 | Suspension | Round cell | Human | Leukemia | Blood | Human acute myeloid leukemia | DSMZ | ACC 99 | 80-90% alpha-MEM + 10-20% FBS |
NGTCBLEU018 | OCI-AML5 | Suspension | Round cell | Human | Leukemia | Blood | Human acute myeloid leukemia | DSMZ | ACC 247 | 70% alpha-MEM + 20% FBS + 10% vol conditioned medium of cell line 5637 |
NGTCBLEU019 | OCI-M2 | Suspension | Round cell | Human | Leukemia | Blood | Leukemia | RPMI1640 + 10% FBS | ||
NGTCBLEU020 | RAW264.7 | Adherent | Round cell | Mouse | Leukemia | Blood | Abelson murine leukemia virus-induced tumor | DMEM + 10% FBS | ||
NGTCBLEU021 | RS4;11 | Suspension | Round cell | Human | Leukemia | Blood | Acute lymphoblastic leukemia | RPMI1640 + 10% FBS | ||
NGTCBLEU022 | Reh | Suspension | Round cell | Human | Leukemia | Blood | Acute Llymphocytic leukemia | ATCC | CRL-8286 | RPMI1640 + 10% FBS |
NGTCBLEU023 | THP-1 | Suspension | Round cell | Human | Leukemia | Blood | Acute monocytic leukemia | ATCC | TIB-202 | RPMI1640 + 10% FBS |
NGTCBLEU024 | WEHI-3 | Suspension | Round cell | Mouse | Leukemia | Blood | Leukemia | ATCC | TIB-68 | IMDM + 10% FBS |
NGTCBLUN001 | 95-D | Adherent | Epithelial | Human | Lung Cancer | Lung | Adenocarcinoma | RPMI1640 + 10% FBS | ||
NGTCBLUN002 | A549 | Adherent | Epithelial | Human | Lung Cancer | Lung | ATCC | CCL-185 | RPMI1640 + 10% FBS | |
NGTCBLUN003 | Calu-1 | Adherent | Epithelial | Human | Lung Cancer | Lung | Epidermoid carcinoma, Grade III | ATCC | HTB-54 | RPMI1640 + 10% FBS |
NGTCBLUN004 | Calu-3 | Adherent | Epithelial | Human | Lung Cancer | Lung | Adenocarcinoma | ATCC | HTB-55 | MEM + 10% FBS |
NGTCBLUN005 | Calu-6 | Adherent | Epithelial | Human | Lung Cancer | Lung | Anaplastic carcinoma | ATCC | HTB-56 | RPMI1640 + 10% FBS |
NGTCBLUN006 | DMS 114 | Adherent | Epithelial | Human | Lung Cancer | Lung | Small cell lung cancer | ATCC | CRL-2066 | RPMI1640 + 10% FBS |
NGTCBLUN007 | DMS 53 | Adherent | Epithelial | Human | Lung Cancer | Lung | Small cell lung cancer | ECACC | 95062823 | Waymouth's MB 752/1 + 2mM Glutamine + 10% H.I. FBS |
NGTCBLUN008 | EBC-1 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | JCRB | JCRB0820 | MEM + 10% FBS |
NGTCBLUN009 | GLC15 | Adherent | Epithelial | Human | Lung Cancer | Lung | RPMI1640 + 10% FBS | |||
NGTCBLUN010 | HAC-84 | Adherent | Epithelial | Human | Lung Cancer | Lung | RPMI1640 + 10% FBS | |||
NGTCBLUN011 | HARA | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | JCRB | JCRB1080.0 | RPMI1640 + 10% FBS |
NGTCBLUN012 | HARA-B | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | JCRB | JCRB1080.1 | RPMI1640 + 10% FBS |
NGTCBLUN013 | HCC-1195 | Adherent | Epithelial | Human | Lung Cancer | Lung | Adeno-squamous cell carcinoma | KCLB | 71195 | RPMI1640 + 10% FBS |
NGTCBLUN014 | HCC-15 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC | KCLB | 70015 | RPMI1640 + 10% FBS |
NGTCBLUN015 | HCC-1588 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | KCLB | 71588 | RPMI1640 + 10% FBS |
NGTCBLUN016 | HCC-2279 | Adherent | Epithelial | Human | Lung Cancer | Lung | Adeno-squamous cell carcinoma | KCLB | 72279 | RPMI1640 + 10% FBS |
NGTCBLUN017 | HCC-366 | Adherent | Epithelial | Human | Lung Cancer | Lung | Adeno-squamous cell carcinoma | KCLB | 70366 | RPMI1640 + 10% FBS |
NGTCBLUN018 | HCC-78 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC | DSMZ | ACC 563 | RPMI1640 + 10% FBS |
NGTCBLUN019 | HCC-95 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | KCLB | 70095 | RPMI1640 + 10% FBS |
NGTCBLUN020 | HCC827 | Adherent | Epithelial | Human | Lung Cancer | Lung | Adenocarcinoma | ATCC | CRL-2868 | RPMI1640 + 10% FBS |
NGTCBLUN021 | HX 147 | Adherent | Epithelial | Human | Lung Cancer | Lung | Large cell lung carcinoma | F12 + 10% FBS | ||
NGTCBLUN022 | KNS-62 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | MEM + 10% FBS | ||
NGTCBLUN023 | L115 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | RPMI1640 + 10% FBS + 1% Sodium Pyruvate + 1% NEAA | ||
NGTCBLUN024 | LC-1 sq | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | JCRB | JCRB0258 | RPMI1640/F12(1:1 ) + 10% FBS |
NGTCBLUN025 | LC-2/ad | Adherent | Epithelial | Human | Lung Cancer | Lung | Adenocarcinoma | ECACC | 94072247 | RPMI 1640:HAMS F12 (1:1) + 2mM Glutamine + 10% FBS |
NGTCBLUN026 | LK-2 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | JCRB | JCRB0829 | RPMI1640 + 10% FBS |
NGTCBLUN027 | LOU-NH91 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | DSMZ | ACC 393 | RPMI1640 + 20% H.I. FBS |
NGTCBLUN028 | LUDLU-1 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | ECACC | 92012463 | RPMI1640 + 10% FBS |
NGTCBLUN029 | NCI-H1299 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC | ATCC | CRL-5803 | RPMI1640 + 10% FBS |
NGTCBLUN030 | NCI-H1385 | Suspension | Epithelial | Human | Lung Cancer | Lung | NSCLC, Stage IIIA | ATCC | CRL-5867 | RPMI1640 + 10% FBS |
NGTCBLUN031 | NCI-H1417 | Suspension | Epithelial | Human | Lung Cancer | Lung | Small cell lung cancer | ATCC | CRL-5869 | RPMI1640 + 1mM soodium Pyruvate + 2.5 g/L Glucose +10% FBS |
NGTCBLUN032 | NCI-H1437 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma, Stage I | ATCC | CRL-5872 | RPMI1640 + 10% FBS |
NGTCBLUN033 | NCI-H1648 | Adherent | Epithelial | Human | Lung Cancer | Lung | Adenocarcinoma, Stage IIIA | ATCC | CRL-5882 | BEGM kit +10% FBS |
NGTCBLUN034 | NCI-H1650 | Adherent | Epithelial | Human | Lung Cancer | Lung | Adenocarcinoma, Stage IIIB | ATCC | CRL-5883 | RPMI1640 + 10% FBS |
NGTCBLUN035 | NCI-H1688 | Adherent | Epithelial | Human | Lung Cancer | Lung | Small cell lung cancer | ATCC | CCL-257 | RPMI1640 + 10% FBS |
NGTCBLUN036 | NCI-H1703 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma, Stage I | ATCC | CRL-5889 | RPMI1640 + 10% FBS |
NGTCBLUN037 | NCI-H1781 | Adherent | Epithelial | Human | Lung Cancer | Lung | Adenocarcinoma, Stage IIIB | ATCC | CRL-5894 | RPMI1640 + 10% FBS |
NGTCBLUN038 | NCI-H1793 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma | ATCC | CRL-5896 | BEGM kit +10%FBS |
NGTCBLUN039 | NCI-H1869 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Stage IV | ATCC | CRL-5900 | BEGM kit +10%FBS |
NGTCBLUN040 | NCI-H196 | Adherent | Epithelial | Human | Lung Cancer | Lung | Small cell lung cancer | ATCC | CRL-5823 | RPMI1640 + 10% FBS |
NGTCBLUN041 | NCI-H1975 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma | ATCC | CRL-5908 | RPMI1640 + 10% FBS |
NGTCBLUN042 | NCI-H1993 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma, Stage IIIA | ATCC | CRL-5909 | BEGM kit +10%FBS |
NGTCBLUN043 | NCI-H2066 | Adherent | Epithelial | Human | Lung Cancer | Lung | Mixed, adenocarcinoma, squamouse cell carcinoma | ATCC | CRL-5917 | DMEM:F12 + 0.01 mg/ml Transferrin + 30 nM Sodium selenite + 10 nM Hydrocortisone + 10 nM beta-estradiol + 2 mM L-glutamine + 5% FBS |
NGTCBLUN044 | NCI-H2085 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma | ATCC | CRL-5921 | BEGM kit +10%FBS |
NGTCBLUN045 | NCI-H2122 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma, Stage IV | ATCC | CRL-5985 | RPMI1640 + 10% FBS |
NGTCBLUN046 | NCI-H2126 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma | ATCC | CCL-256 | BEGM kit +10%FBS |
NGTCBLUN047 | NCI-H2170 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | ATCC | CRL-5928 | RPMI1640 + 10% FBS |
NGTCBLUN048 | NCI-H2228 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma | ATCC | CRL-5935 | RPMI1640 + 10% FBS |
NGTCBLUN049 | NCI-H226 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | ATCC | CRL-5826 | RPMI1640 + 10% FBS |
NGTCBLUN050 | NCI-H2286 | Adherent | Epithelial | Human | Lung Cancer | Lung | Small cell lung cancer, mixed adenocarcinoma and squamous cell carcinoma, Stage I | ATCC | CRL-5938 | BEGM kit +10%FBS |
NGTCBLUN051 | NCI-H2291 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma | ATCC | CRL-5939 | DMEM + 10% FBS |
NGTCBLUN052 | NCI-H23 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma | ATCC | CRL-5800 | RPMI1640 + 10% FBS |
NGTCBLUN053 | NCI-H3122 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC | ATCC | CRL-5803 | RPMI1640 + 10% FBS |
NGTCBLUN054 | NCI-H322 | Adherent | Epithelial | Human | Lung Cancer | Lung | Bronchioalveolar carcinoma | ECACC | 95111734 | RPMI1640 + 10% FBS |
NGTCBLUN055 | NCI-H3255 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC | ATCC | CRL-2882 | BEGM kit +10%FBS |
NGTCBLUN056 | NCI-H358 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC | ATCC | CRL-5807 | RPMI1640 + 10% FBS |
NGTCBLUN057 | NCI-H441 | Adherent | Epithelial | Human | Lung Cancer | Lung | Papillary adenocarcinoma | ATCC | HTB-174 | RPMI1640 + 10% FBS |
NGTCBLUN058 | NCI-H460 | Adherent | Epithelial | Human | Lung Cancer | Lung | Large cell lung carcinoma | ATCC | HTB-177 | RPMI1640 + 10% FBS |
NGTCBLUN059 | NCI-H520 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | ATCC | HTB-182 | RPMI1640 + 10% FBS |
NGTCBLUN060 | NCI-H522 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma, Stage II | ATCC | CRL-5810 | RPMI1640 + 10% FBS |
NGTCBLUN061 | NCI-H526 | Suspension | Epithelial | Human | Lung Cancer | Lung | Variant small cell lung cancer, Stage E | ATCC | CRL-5811 | RPMI1640 + 10% FBS |
NGTCBLUN062 | NCI-H596 | Adherent | Epithelial | Human | Lung Cancer | Lung | Adenosquamous carcinoma | ATCC | HTB-178 | RPMI1640 + 10% FBS |
NGTCBLUN063 | NCI-H647 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenosquamous carcinoma, Stage IIIA | ATCC | CRL-5834 | RPMI1640 + 10% FBS |
NGTCBLUN064 | NCI-H810 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma, Stage II | ATCC | CRL-5816 | BEGM kit +10%FBS |
NGTCBLUN065 | NCI-H838 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma, Stage IIIB | ATCC | CRL-5844 | RPMI1640 + 10% FBS |
NGTCBLUN066 | NCI-H889 | Suspension | Floating aggregates | Human | Lung Cancer | Lung | Small cell lung cancer, Stage E | ATCC | CRL-5817 | RPMI1640 + 10% FBS |
NGTCBLUN067 | Oka-C-1 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | JCRB | JCRB1343 | RPMI1640 + 10% FBS |
NGTCBLUN068 | PC-9 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC | RPMI1640 + 10% FBS | ||
NGTCBLUN069 | PC14PE6 | Mixed suspension and adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma | DMEM + 10% FBS | ||
NGTCBLUN070 | RERF-LC-AI | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | RIKEN | RCB0444 | MEM + 10% FBS |
NGTCBLUN071 | RERF-LC-Sq1 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | JCRB | JCRB1019 | RPMI1640 + 10% FBS |
NGTCBLUN072 | SHP-77 | Loosely adherent | Floating aggregates | Human | Lung Cancer | Lung | Small cell lung cancer | ATCC | CRL-2195 | RPMI1640 + 10% FBS |
NGTCBLUN073 | SK-MES-1 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | KCLB | 30058 | RPMI1640 + 10% FBS |
NGTCBLUN074 | SPC-A1 | Adherent | Epithelial | Human | Lung Cancer | Lung | NSCLC, Adenocarcinoma | RPMI1640 + 10% FBS | ||
NGTCBLUN075 | SW1573 | Adherent | Epithelial | Human | Lung Cancer | Lung | Alveolar cell carcinoma | ATCC | CRL-2170 | L15 + 10% FBS |
NGTCBLUN076 | SW1271 | Adherent | Epithelial | Human | Lung Cancer | Lung | Small cell lung cancer | ATCC | CRL-2177 | L15 + 10% FBS |
NGTCBLUN077 | SW900 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma, Grade IV | ATCC | HTB-59 | RPMI1640 + 10% FBS |
NGTCBLUN078 | VMRC-LCP | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | JCRB | JCRB0103 | MEM + 1% NEAA + 10% FBS |
NGTCBLUN079 | YTMLC-90 | Adherent | Epithelial | Human | Lung Cancer | Lung | Squamous cell carcinoma | RPMI1640 + 10% FBS | ||
NGTCBLYM001 | JEKO-1 | Suspension | Lymphoblast | Human | Lymphoma | Blood | Mantle Cell Lymphoma | ATCC | CRL-3006 | RPMI1640 + 20% FBS |
NGTCBLYM002 | NAMALWA | Suspension | Lymphoblast | Human | Lymphoma | B Lymphocyte | Burkitt's Lymphoma | ATCC | CRL-1432 | RPMI1640 + 10% FBS |
NGTCBLYM003 | NK-92 | Suspension | Lymphoblast | Human | Lymphoma | Natural killer cell | Non-Hodgkin's Lymphoma | ATCC | CRL-2407 | Alpha-MEM + 2 mM L-glutamine + 1.5 g/L sodium bicarbonate + 0.2 mM inositol + 0.1 mM 2-mercaptoethanol + 0.02 mM folic acid + 100-200 U/ml recombinant IL-2 + 12.5% horse serum + 12.5% FBS |
NGTCBLYM004 | OCI-LY-19 | Suspension | Lymphoblast | Human | Lymphoma | Bone marrow | B cell lymphoma | DSMZ | ACC 528 | 80-90% alpha-MEM + 10-20% FBS |
NGTCBLYM005 | Raji | Suspension | Epithelial | Human | Lymphoma | B Lymphocyte | Burkitt's Lymphoma | ATCC | CCL-86 | RPMI1640 + 10% FBS |
NGTCBLYM006 | Ramos (RA1) | Suspension | Lymphoblast | Human | Lymphoma | B Lymphocyte | Burkitt's Lymphoma | ATCC | CRL-1596 | RPMI1640 + 10% FBS |
NGTCBLYM007 | SC-1 | Suspension | Lymphoblast | Human | Lymphoma | B Lymphocyte | B cell lymphoma | ATCC | CRL-8756 | RPMI1640 + 10% FBS |
NGTCBLYM008 | U-937 | Suspension | Lymphoblast | Human | Lymphoma | Lymphocyte | Histiocytic lymphoma | ATCC | CRL-1593.2 | RPMI1640 + 10% FBS |
NGTCBLYM009 | WSU DLCL2 | Suspension | Lymphoblast | Human | Lymphoma | B Lymphocyte | B-cell Non-Hodgkin's Lymphoma | DSMZ | ACC 575 | RPMI1640 + 10% FBS |
NGTCBMEL001 | A-375 | Adherent | Epithelial | Human | Malignant melanoma | Skin | Malignant melanoma | ATCC | CRL-1619 | DMEM + 10% FBS |
NGTCBMEL002 | A2058 | Adherent | Epithelial | Human | Malignant melanoma | Skin | Malignant melanoma | ATCC | CRL-11147 | DMEM + 10% FBS |
NGTCBMEL003 | WI 38 VA13 2RA | Adherent | Epithelial | Human | Malignant melanoma | Skin | Malignant melanoma | ECACC | DMEM + 10% FBS | |
NGTCBNAS001 | C666-1 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS002 | CNE-2Z | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS003 | CNE1 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS004 | CNE1-lmp1 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS005 | CNE2 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS006 | HEP-2 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS007 | HK-1 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS008 | HNE1 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS009 | HNE2 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS010 | HNE2-LMP1 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS011 | HNE3 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS012 | HONE1 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBNAS013 | SUNE-1 | Adherent | Epithelial | Human | Nasopharyngeal Carcinoma | Nasopharynx | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBOVA001 | A2780 | Adherent | Epithelial | Human | Ovarian Cancer | Ovary | Ovarian Cancer | ECACC | 93112519 | RPMI1640 + 10% FBS |
NGTCBOVA002 | Caov-3 | Adherent | Epithelial | Human | Ovarian Cancer | Ovary | Adenocarcinoma | ATCC | HTB-75 | DMEM + 10% FBS |
NGTCBOVA003 | MDAH2774 | Adherent | Epithelial | Human | Ovarian Cancer | Ovary | Ovarian Cancer | ATCC | CRL-10303 | RPMI1640 + 10% FBS |
NGTCBOVA004 | NIH:OVCAR3 | Adherent | Epithelial | Human | Ovarian Cancer | Ovary | Adenocarcinoma | ATCC | HTB-161 | RPMI1640 + 20% FBS |
NGTCBOVA005 | OAW42 | Adherent | Epithelial | Human | Ovarian Cancer | Ovary | Ovarian Cancer | ECACC | 85073102 | DMEM + 2 mM Glutamine + 1 mM Sodium Pyruvate + 20 IU/l Bovine Insulin + 10% FBS |
NGTCBOVA006 | OC 316 | Adherent | Epithelial | Human | Ovarian Cancer | Ovary | Adenocarcinoma | ICLC | HTL98014 | RPMI1640 + 10% FBS |
NGTCBOVA007 | OVCAR5 | Adherent | Epithelial | Human | Ovarian Cancer | Ovary | Ovarian Cancer | RPMI1640 + 10% FBS | ||
NGTCBOVA008 | OVCAR8 | Adherent | Epithelial | Human | Ovarian Cancer | Ovary | Ovarian Cancer | RPMI1640 + 10% FBS | ||
NGTCBOVA009 | SK-OV-3 | Adherent | Epithelial | Human | Ovarian Cancer | Ovary | Ovarian Cancer | ATCC | HTB-77 | F12 + 10% FBS |
NGTCBPAN001 | AsPC-1 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ATCC | CRL-1682 | RPMI1640 + 10% FBS |
NGTCBPAN002 | BxPC-3 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ATCC | CRL-1687 | RPMI1640 + 10% FBS |
NGTCBPAN003 | CFPAC-1 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ATCC | IMEM + 10% FBS | |
NGTCBPAN004 | Capan-1 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ATCC | HTB-79 | RPMI1640 + 7% FBS |
NGTCBPAN005 | Capan-2 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ATCC | HTB-80 | RPMI1640 + 10% FBS |
NGTCBPAN006 | HPAC | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ATCC | CRL-2119 | DMEM/F12 + 10% FBS + 2-L-Glu + 0.02 mg/ml insulin + 0.005 mg/ml transferrin + 40 ng/ml hydrocortisone + 10 ng/ml EGF |
NGTCBPAN007 | HPAF-II | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ATCC | CRL-1997 | MEM + 10% FBS |
NGTCBPAN008 | HUP-T3 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | DSMZ | ACC 259 | MEM + 10% FBS + 1% NEAA + 1% Sodium Pyruvate |
NGTCBPAN009 | Hs 766T | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ATCC | HTB-134 | DMEM + 10% FBS |
NGTCBPAN010 | HuP-T4 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | MEM + 10% FBS + 2 mM L-Glu + 0.1 mM NEAA + 1 mM Na pyruvate | ||
NGTCBPAN011 | KP-4 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Pancreatic ductal cell carcinoma | JCRB | JCRB0182 | IMDM + 20% FBS |
NGTCBPAN012 | MIA PaCa-2 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Carcinoma | ATCC | CRL-1420 | DMEM + 10% FBS |
NGTCBPAN013 | OAW28 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ECACC | 85101601 | DMEM + 10% FBS |
NGTCBPAN014 | PANC-1 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Epithelioid carcinoma | ATCC | CRL-1469 | DMEM + 10% FBS |
NGTCBPAN015 | PNT1A | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ECACC | 95012614 | DMEM + 10% FBS |
NGTCBPAN016 | PSN1 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | ECACC | 94060601 | RPMI1640 + 10% FBS | |
NGTCBPAN017 | Panc-89 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | RPMI1640 + 10% FBS | |||
NGTCBPAN018 | QGP-1 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Pancreatic carcinoma of islet cell | JCRB | JCRB0183 | RPMI1640 + 10% FBS |
NGTCBPAN019 | SU86.86 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | RPMI1640 + 10% FBS | |||
NGTCBPAN020 | SW1910 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | RPMI1640 + 10% FBS | ||
NGTCBPAN021 | SW1990 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | Adenocarcinoma | ATCC | CRL-2172 | L15 + 10% FBS |
NGTCBPAN022 | T3M-4 | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | RIKEN | RCB1021 | F10 + 10% FBS | |
NGTCBPAN023 | YAPC | Adherent | Epithelial | Human | Pancreatic Cancer | Pancreas | DSMZ | ACC 382 | RPMI1640 + 10% Hi FBS | |
NGTCBPHA001 | Detroit 562 | Adherent | Epithelial | Human | Pharynx Carcinoma | Pharynx | Carcinoma | ATCC | CCL-138 | MEM + 1% NEAA + 1mM Sodium Pyruvate + 0.1% Lactalbumin hydrolysate + 10% FBS |
NGTCBPHA002 | FaDu | Adherent | Epithelial | Human | Pharynx Carcinoma | Pharynx | Squamous cell carcinoma | ATCC | HTB-43 | MEM + 10% FBS |
NGTCBPHA003 | RWPE-1 | Adherent | Epithelial | Human | Pharynx Carcinoma | Pharynx | Carcinoma | ATCC | CRL-11609 | RPMI1640 + 10% FBS |
NGTCBPRO001 | 22Rv1 | Adherent | Epithelial | Human | Prostate Cancer | Prostate | Carcinoma | ATCC | CRL-2505 | RPMI1640 + 10% FBS |
NGTCBPRO002 | A498 | Adherent | Epithelial | Human | Prostate Cancer | Prostate | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBPRO003 | CHP-212 | Adherent | Epithelial | Human | Prostate Cancer | Prostate | Neuroblastoma | RPMI1640 + 10% FBS | ||
NGTCBPRO004 | DU145 | Adherent | Epithelial | Human | Prostate Cancer | Prostate | Carcinoma | ATCC | HTB-81 | RPMI1640 + 10% FBS |
NGTCBPRO005 | LAPC4 | Adherent | Epithelial | Human | Prostate Cancer | Prostate | Carcinoma | IMDM + 10% FBS | ||
NGTCBPRO006 | LNCAP | Adherent | Fibroblast | Human | Prostate Cancer | Prostate | Carcinoma | ATCC | CRL-1740 | 85-90% RPMI 1640 + 10-15% FBS |
NGTCBPRO007 | NB1 | Adherent | Fibroblast | Human | Prostate Cancer | Prostate | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBPRO008 | PC 346C | Adherent | Fibroblast | Human | Prostate Cancer | Prostate | Carcinoma | RPMI1640 + 10% FBS | ||
NGTCBPRO009 | PC-3 | Adherent | Epithelial | Human | Prostate Cancer | Prostate | Adenocarcinoma, Grade IV | ATCC | CRL-1435 | F12 + 10% FBS |
NGTCBSKI001 | A431 | Adherent | Epithelial | Human | Skin Cancer | Skin, epidermis | Epidermoid Carcinoma | ATCC | CRL-1555 | alpha-MEM + 10% FBS |
NGTCBTHY001 | 8305C | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | ECACC | 94090183 | MEM + 10% FBS + 1% NEAA |
NGTCBTHY002 | 8505C | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | ECACC | 94090184 | MEM + 10% FBS + 1% NEAA |
NGTCBTHY003 | ASH-3 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Anaplastic thyroid carcinoma | JCRB | JCRB1073 | DMEM:RPMI 1640 (1:1) + 10% FBS |
NGTCBTHY004 | B-CPAP | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | DSMZ | ACC 273 | 90% RPMI 1640 + 10% h.i. FBS |
NGTCBTHY005 | BHT-101 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | DMEM + 20% FBS + 0.5% human serum (+ 0.005 IU/ml TSH + 5 ug/ml human insulin) | ||
NGTCBTHY006 | CAL-62 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | DSMZ | ACC 448 | 90-95% DMEM + 5-10% h.i. FBS |
NGTCBTHY007 | CGTH-W-1 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | RPMI1640 + 10% FBS | ||
NGTCBTHY008 | FTC-133 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | ECACC | 94060901 | DMEM/F12 (1:1) + 10% FBS |
NGTCBTHY009 | FTC-238 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Follicular thyroid carcinoma | ECACC | 94060902 | DMEM/F12 (1:1) + 5% FBS |
NGTCBTHY010 | HTC/C3 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | JCRB | JCRB0164 | DMEM + 10% FBS |
NGTCBTHY011 | IHH-4 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Papillary thyroid carcinoma | JCRB | JCRB1079 | DMEM/RPMI1640 (1:1) + 10% FBS |
NGTCBTHY012 | KHM-5M | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | JCRB | JCRB0148 | RPMI1640 + 10% FBS |
NGTCBTHY013 | KMH-2 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | JCRB | JCRB1066 | DMEM/RPMI1640 (1:1) + 10% FBS |
NGTCBTHY014 | MB-1 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | RPMI1640 + 10% FBS | ||
NGTCBTHY015 | ML-1 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Follicular thyroid carcinoma | DMEM + 10-20% FBS + 2 mM L-Glutamine + 1 mM sodium pyruvate | ||
NGTCBTHY016 | MZ-CRC-1 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | DMEM + 10% FBS | ||
NGTCBTHY017 | NIM | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | DMEM + 10% FBS | ||
NGTCBTHY018 | RO82-W-1 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Follicular thyroid carcinoma | ECACC | 92030502 | DMEM/F12 (1:1) + 10% FBS |
NGTCBTHY019 | S-117 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Sarcoma | RPMI1640 + 10% FBS | ||
NGTCBTHY020 | SNU-790 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | KCLB | 00790 | RPMI1640 + 10% FBS |
NGTCBTHY021 | SNU-80 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | KCLB | 00080 | RPMI1640 + 10% FBS |
NGTCBTHY022 | SW13 | Adherent | Epithelial | Human | Thyroid Carcinoma | Adrenal gland/cortex | Primary small cell carcinoma, Grade IV | ATCC | CCL-105 | RPMI1640 + 10% FBS |
NGTCBTHY023 | SW579 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Squamous cell carcinoma | ATCC | HTB-107 | L15 + 10% FBS |
NGTCBTHY024 | TCO-1 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | JCRB | JCRB0239 | DMEM + 10% FBS |
NGTCBTHY025 | TPC-1 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Thyroid anaplastic carcinoma | DMEM + 10% FBS | ||
NGTCBTHY026 | TT | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid, medulla | Carcinoma | ATCC | CRL-1803 | F12K + 10% FBS |
NGTCBTHY027 | TT2609-C02 | Adherent | Epithelial | Human | Thyroid Carcinoma | Thyroid | Follicular thyroid carcinoma | RPMI1640 + 10% FBS |
![联系客服](javascript: Mobi.showWeChatService("//6309039.s21i.faiusr.com/2/ABUIABACGAAg4JO47gUosKjkywUwrgM4rgM.jpg");){kind=link}